Xiuning Le, Deputy Section Chief of Thoracic Medical Oncology at MD Anderson Cancer Center, shared a post on LinkedIn:
“ORCHARD (NCT03944772) is a standout example of a precision oncology guided platform clinical trial. This is a phase II biomarker-directed platform study after progression on first-line osimertinib in EGFR-mutant NSCLC. We studied 10 different treatments in molecularly defined groups. Two combinations: osimertinib+savolitinib and osimertinib+dato-dxd advanced to phase 3 development.
ORCHARD’s value is that it truly OPERATIONALIZES precision oncology:
- uses a modular design to allow arms to be added/closed,
- generates early efficacy signals for randomized phase 3 studies,
- allows effective study of rare resistance subsets,
- helps to define post-osimertinib standard-of-care of testing procedure and treatments.
It was a fantastic team work with co-investigators Jonathan Riess, Joop de Langen, Lizza Hendriks, Helena Yu, Zofia Piotrowska, Sarah Goldberg, Jonathan Goldman, as well as sponsor colleagues Paula Goodman Fraenkel, Myles Mckiernan, Nabil Chehab, Eder Martins, Matt Hellmann and many many team members!”
Title: ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib
Authors: Jonathan W. Riess, Adrianus J. de Langen, Santiago Ponce, Sarah B. Goldberg, Zofia Piotrowska, Jonathan W. Goldman, Xiuning Le, Byoung Chul Cho, Yasuto Yoneshima, Helen Ambrose, Riccardo Cavazzina, Kwan Ho Tang, James Lau, Helena A. Yu
Read the Full Article.
Other Articles Featuring Xiuning Le on OncoDaily.